Plasma cell-free DNA as a biomarker for the diagnosis of acute coronary syndrome

doi:10.3969/j.issn.1673-8640.2016.12.003

Abstract

Abstract:

Objective To investigate the significance of plasma cell-free DNA（cfDNA） as a biomarker for the diagnosis of acute coronary syndrome（ACS） by choosing Alu as a target gene.Methods Blood specimens of 140 patients with ACS（ACS group） and 60 healthy subjects（healthy control group） were collected. A branched DNA（bDNA） assay based on Alu gene was used to determine the concentration of cfDNA,and the serial changes of cfDNA concentrations were observed dynamically in some ACS patients before and after percutaneous coronary intervention（PCI）. The concentrations of cardiac troponin I（cTnI）,creatine kinase-MB（CK-MB） and myoglobin（MYO） were determined by chemiluminescence assay,and the correlations of cfDNA with cTnI,CK-MB and MYO were analyzed. Receiver operating characteristic （ROC） curve was performed for evaluating the significance of cfDNA in the diagnosis of ACS. Results The concentration of cfDNA was higher in ACS group [2 550.3（969.9-4 866.4） ng/mL] than that in healthy control group [118.3（81.1-221.1） ng/mL,P<0.001]. The concentration of cfDNA was decreased in 10 patients after PCI,and there was no statistical significance for cfDNA concentration before and after PCI（P>0.05）. No correlation was found between cfDNA concentration and cTnI,CK-MB,MYO in patients with ACS （r²=0.031,0.152 and 0.217,P>0.05）. ROC curves showed that the areas under the curves（0.95） and the sensitivities of cfDNA（82.76%） were better than those of cTnI（0.57 and 22.41%）,CK-MB（0.81 and 20.69%） and MYO（0.64 and 10.34%）. The specificities of the 4 parameters were all 100.00%. Conclusions Plasma concentration of cfDNA is increased in ACS patients,its diagnosis significance is better than those of commonly-used myocardial biomarkers,and cfDNA may be an important biomarker for the diagnosis of ACS.

Key words: Cell-free DNA, Alu gene, Biomarkers, Acute coronary syndrome

CLC Number:

Q503

CONG Hui, JING Rongrong, WANG Huimin, WU Xiaohui, CHU Haidan, FAN Mengkang, JU Shaoqin. Plasma cell-free DNA as a biomarker for the diagnosis of acute coronary syndrome[J]. Laboratory Medicine, 2016, 31(12): 1021-1025.

Figures/Tables 5

References 11

1	朱立岳,关明,康志华,等. 血清TFPI-2 基因甲基化在胃癌诊断中的临床价值[J]. 检验医学,2014,29(7):712-717.
2	ILES RK,SHAHPARI ME,CUCKLE H,et al. Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy[J]. Clin Proteomics,2015,12(1):9.
3	YI J,ZHANG Y,ZHANG Y,et al. Increased plasma cell-free DNA level during HTNV infection: correlation with disease severity and virus load[J]. Viruses,2014,6(7):2723-2734.
4	PARK SJ,KIM YH,LEE SR,et al. Gain of a new exon by a lineage-specific Alu element-integration event in the BCS1L gene during primate evolution[J]. Mol Cells,2015,38(11):950-958.
5	WILDSCHUTTE JH,BARON A,DIROFF NM,et al. Discovery and characterization of Alu repeat sequences via precise local read assembly[J]. Nucleic Acids Res,2015,43(21):10292-10307.
6	SHIMONY A,ZAHGER D,GILUTZ H,et al. Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients[J]. Acute Card Care,2010,12(3):109-111.
7	LOU X,HOU Y,LIANG D,et al. A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction[J]. Int J Mol Med,2015,35(1):72-80.
8	PATEL PD,ARORA RR. Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction[J]. Am J Ther,2010,17(1):e24-e40.
9	QI J,QIAN C,SHI W,et al. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer[J]. Clin Biochem,2013,46(1-2):64-69.
10	DESTOUNI A,VRETTOU C,ANTONATOS D,et al. Cell-free DNA levels in acute myocardial infarction patients during hospitalization[J]. Acta Cardiol,2009,64(1):51-57.
11	CHANG CP,CHIA RH,WU TL,et al. Elevated cell-free serum DNA detected in patients with myocardial infarction[J]. Clin Chim Acta,2003,327(1-2):95-101.

组别	例数	年龄（岁）	性别		FPG（mmol/L）	TC（mmol/L）	TG（mmol/L）
组别	例数	年龄（岁）	男	女	FPG（mmol/L）	TC（mmol/L）	TG（mmol/L）
ACS 组	140	66.2±10.1	104	36	6.3（5.5~7.3）	4.33（3.68~5.27）	1.38（0.95~1.82）
正常对照组	60	59.9±12.4	39	21	5.4（4.9~6.2）	4.71（3.88~5.25）	1.09（0.82~1.78）
P值		0.002	0.106		0.003	0.005	0.005
组别	LDL-C（mmol/L）		HDL-C（mmol/L）		Lp（a）（mg/L）	尿素（mmol/L）	Cr（μmol/L）
ACS 组	2.68（2.16~3.19）		1.11（1.12~1.35）		155（74~295）	5.3（4.5~6.7）	72.7（63.2~87.0）
正常对照组	2.63（2.09~3.23）		1.35（1.09~1.77）		105（60~207）	5.0（4.2~6.7）	64.2（55.7~79.4）
P值	0.512		0.007		0.002	0.633	<0.001

组别	例数	年龄（岁）	性别		FPG（mmol/L）	TC（mmol/L）	TG（mmol/L）
组别	例数	年龄（岁）	男	女	FPG（mmol/L）	TC（mmol/L）	TG（mmol/L）
ACS 组	140	66.2±10.1	104	36	6.3（5.5~7.3）	4.33（3.68~5.27）	1.38（0.95~1.82）
正常对照组	60	59.9±12.4	39	21	5.4（4.9~6.2）	4.71（3.88~5.25）	1.09（0.82~1.78）
P值		0.002	0.106		0.003	0.005	0.005
组别	LDL-C（mmol/L）		HDL-C（mmol/L）		Lp（a）（mg/L）	尿素（mmol/L）	Cr（μmol/L）
ACS 组	2.68（2.16~3.19）		1.11（1.12~1.35）		155（74~295）	5.3（4.5~6.7）	72.7（63.2~87.0）
正常对照组	2.63（2.09~3.23）		1.35（1.09~1.77）		105（60~207）	5.0（4.2~6.7）	64.2（55.7~79.4）
P值	0.512		0.007		0.002	0.633	<0.001

[1]	FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883.
[2]	LIANG Dong, MEI Yue, WANG Tengjiao, YU Dong. Characteristic of blood microbiota of postoperative sepsis based on cfDNA NGS [J]. Laboratory Medicine, 2023, 38(8): 753-759.
[3]	HE Chengshan, YAO Xiaoyang, JIANG Xiudi, LU Zhicheng. Microarray chemiluminescence immunoassay for quantitative detection of cardiac troponin I autoantibodies and preliminary clinical applications [J]. Laboratory Medicine, 2021, 36(3): 318-324.
[4]	DU Kun, YAN Jianhua, CHEN Ming, YANG Junyao, ZHANG Guanghui. Role of risk stratification and prognosis of sST2 in acute coronary syndrome patients after percutaneous coronary intervention [J]. Laboratory Medicine, 2021, 36(10): 1020-1025.
[5]	DING Hui, LI Zhumeng, WANG Yin, WANG Dong, SHENG Huiming. Analysis of serum lipoprotein （a） and homocysteine levels in patients with acute coronary syndrome [J]. Laboratory Medicine, 2019, 34(12): 1082-1087.
[6]	LU Qiuya, LU Yide, SUN Aihua, MA Weiyun, ZHOU Yiqiong, WANG Xuefeng. Thromboelastography-MA parameter in the diagnosis of acute coronary syndrome [J]. Laboratory Medicine, 2018, 33(2): 119-123.
[7]	BO Lei, SHAN Jigang, ZHAO Zhiwen. Research progress of myeloperoxidase in cardiovascular diseases [J]. Laboratory Medicine, 2017, 32(8): 738-743.
[8]	YUAN Yongming, ZHANG Xiaoying, GU Xidong, ZHANG Jue, HAN Qian. Relations of MTHFR gene C677T polymorphism with hyperhomocysteinemia and acute coronary syndrome [J]. Laboratory Medicine, 2017, 32(11): 1013-1016.
[9]	XU Jin.. Improving laboratory diagnosis ability of infectious diseases in children using multiple assays [J]. Laboratory Medicine, 2016, 31(3): 155-158.
[10]	CHEN Qiudan, LIN Yong. Research progress on microRNAs in glioma [J]. Laboratory Medicine, 2016, 31(10): 917-921.
[11]	ZHANG Ping, ZHOU Hongxing, BAI Yang, XU Zhe, SUN Yingxin, WANG Xin, WANG Sujian, ZHANG Hong. Study on the application significance of ischemia modified albumin in early diagnosis of acute coronary syndrome [J]. Laboratory Medicine, 2015, 30(6): 581-584.
[12]	ZHANG Shanfeng, ZHU Fangtao, WANG Mingchen. The significance of early diagnosis of D-dimer in patients with acute aortic dissection and its impact on prognosis [J]. Laboratory Medicine, 2015, 30(4): 321-323.
[13]	YU Pingan, PAN Feng. The clinical significance of ischemia modified albumin and cardiac troponinⅠcombined determination in the diagnosis of acute coronary syndrome [J]. Laboratory Medicine, 2015, 30(3): 234-237.
[14]	NING Li，WEI Dianjun，ZHANG Jingwei. The Level Changes and Clinical Significance of serum EPOin Patients with Acute Coronary Syndrome [J]. , 2013, 28(4): 280-282.
[15]	CHEN Jian. Research on the early diagnosis and risk stratification significance of the determination for serum H-FABP and MPO in elderly patients with NSTE ACS [J]. , 2013, 28(4): 271-275.